Empyema

What is an Empyema?

An empyema is a collection of purulent (pus-filled) fluid and cellular debris within the pleural space, which is the cavity between the lungs and the chest wall. It occurs when pathogens, typically bacteria, seed the pleural cavity following a breach in host defenses, such as pneumonia, thoracic surgery, or trauma. This condition represents an advanced stage of pleural infection characterized by the presence of frank pus and a fibrinous peel (a thick layer of inflammatory tissue) that can entrap the lung.

Clinically, an empyema is distinct from a simple parapneumonic effusion, which is a sterile fluid accumulation associated with pneumonia. The former carries a significantly higher bacterial burden and frequently develops loculations, or small, partitioned pockets of fluid created by fibrin septations. Recognizing this distinction is vital, as delayed drainage is associated with high morbidity, particularly in older adults and immunocompromised individuals.

What causes an Empyema?

Bacteria invade the pleural space during an ongoing parapneumonic process, triggering an intense inflammatory response. Common isolates include the Streptococcus anginosus group, Staphylococcus aureus, and various anaerobes. This immune activation increases vascular permeability and neutrophil recruitment, eventually leading to the deposition of fibrous septations that entrap the infected fluid.

Risk factors for the development of an empyema include prolonged pneumonia, delayed initiation of appropriate antibiotic therapy, diabetes, and underlying immunosuppression. The transition from a simple effusion to an infected collection occurs as the fluid becomes purulent or as bacteria become detectable via Gram stain or culture. When comparing parapneumonic effusion vs empyema, the latter reflects a high-grade localized infection that requires mechanical intervention beyond systemic antibiotics.

What are the signs and symptoms of an Empyema?

Individuals with an empyema typically present with persistent fever, pleuritic chest pain (sharp pain during breathing), and productive cough. Systemic toxicity, malaise, and tachypnea (rapid breathing) often persist despite the administration of standard pneumonia treatments. Physical examination frequently reveals dullness to percussion and decreased breath sounds over the affected side, signaling the presence of significant fluid or a restrictive fibrous rind.

Empyema often presents as a case of pneumonia that fails to improve clinically, with refractory leukocytosis (elevated white blood cell count) and persistent fevers. Thoracentesis (percutaneous aspiration of pleural fluid) in these cases often yields turbid or purulent fluid. Laboratory analysis of this fluid typically reveals a low pH, low glucose, and high lactate dehydrogenase (LDH), reflecting intense metabolic activity by bacteria and neutrophils.

Key Discriminators in Pleural Processes

Feature	Simple Parapneumonic Effusion	Empyema
Fluid Appearance	Clear to cloudy	Turbid to frankly purulent
Pleural Fluid pH	> 7.20	< 7.20
Glucose	> 60 mg/dL	< 60 mg/dL
Loculations on Imaging	Rare	Common
Microbiology	Usually sterile	Often culture positive
Drainage Requirement	Often not urgently	Always required

When comparing empyema vs pleural effusion, the presence of neutrophil-rich pus and loculations warrants more aggressive source control than sterile inflammatory fluid.

How is an Empyema diagnosed?

Diagnosis relies on integrating clinical suspicion with advanced imaging and pleural fluid analysis. Chest ultrasound and contrast-enhanced computed tomography (CT) are essential for identifying loculated collections and thickened visceral or parietal pleura (the membranes surrounding the lungs). Imaging may also reveal a “split pleura sign” or underlying lung abscesses that contribute to the infection.

Thoracentesis serves as the key diagnostic step by confirming the presence of pus or identifying pathogens through Gram stain and culture. Pleural fluid findings such as pH below 7.20, low glucose, and elevated LDH support a complicated parapneumonic effusion or empyema and usually prompt drainage, even when the fluid is not frankly purulent, to prevent the formation of a permanent fibrous rind.

How is an Empyema treated?

Management requires a dual approach: targeted antibiotic therapy and aggressive source control. Empiric antibiotics must cover Streptococcus species, S. aureus, and anaerobes, with the regimen narrowed once culture results are available. Clinicians must ensure the chosen agents effectively penetrate the pleural space and account for local resistance patterns.

Source control begins with thoracostomy (chest tube placement), ideally performed under image guidance to ensure the evacuation of purulent fluid. If loculations prevent adequate drainage, clinicians may employ fibrinolytics or intrapleural enzyme therapy to dissolve the fibrous septations. In cases where a thick pleural peel prevents re-expansion of the lung, video-assisted thoracoscopic surgery (VATS) with decortication is necessary, which involves the surgical removal of the inflammatory layer. Treatment typically lasts 4 to 6 weeks, guided by clinical response and follow-up imaging.

What are the most important facts to know about an Empyema?

• An empyema is a purulent pleural infection that often presents as a complication of bacterial pneumonia and can lead to mechanical lung restriction.
• Pathophysiology involves bacterial seeding of the pleural space, leading to fibrin deposition, loculation, and the eventual formation of a fibrous peel.
• Empyema symptoms like persistent fever, pleuritic chest pain, or failure to improve despite antibiotics should prompt repeat imaging and diagnostic thoracentesis.
• Fluid analysis showing a pH < 7.20 or frank pus helps clinicians differentiate parapneumonic effusion vs empyema.
• Definitive treatment must combine targeted antibiotics with drainage, using fibrinolytics or VATS decortication for complex or chronic collections.